175 related articles for article (PubMed ID: 32344040)
21. Addressing uncertainty in relative effectiveness assessments by HTA organizations.
Vreman RA; Strigkos G; Leufkens HGM; Schünemann HJ; Mantel-Teeuwisse AK; Goettsch WG
Int J Technol Assess Health Care; 2022 Jan; 38(1):e17. PubMed ID: 35094740
[TBL] [Abstract][Full Text] [Related]
22. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
23. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
24. Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.
Berntgen M; Gourvil A; Pavlovic M; Goettsch W; Eichler HG; Kristensen FB
Value Health; 2014 Jul; 17(5):634-41. PubMed ID: 25128058
[TBL] [Abstract][Full Text] [Related]
25. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
26. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
27. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
Bouwman L; Sepodes B; Leufkens H; Torre C
Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
[TBL] [Abstract][Full Text] [Related]
28. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
29. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
30. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of the scope of European Union paediatric investigation plans with corresponding orphan designations.
Ecker A; Mariz S; Naumann-Winter F; Norga K; Barisic I; Girard T; Tomasi P; Mentzer D; Sepodes B
Arch Dis Child; 2018 May; 103(5):427-430. PubMed ID: 29089318
[TBL] [Abstract][Full Text] [Related]
32. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
[TBL] [Abstract][Full Text] [Related]
33. Affordable orphan drugs: a role for not-for-profit organizations.
Davies EH; Fulton E; Brook D; Hughes DA
Br J Clin Pharmacol; 2017 Jul; 83(7):1595-1601. PubMed ID: 28109021
[TBL] [Abstract][Full Text] [Related]
34. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
35. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
Micallef J; Blin O
Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
37. Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations.
Madrid Paredes J; Versteeg JW; Vreman RA; Bloem LT
Clin Pharmacol Ther; 2024 Jul; 116(1):136-146. PubMed ID: 38505926
[TBL] [Abstract][Full Text] [Related]
38. Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe.
Fregonese L; Greene L; Hofer M; Magrelli A; Naumann-Winter F; Larsson K; Sheean M; Stoyanova-Beninska V; Tsigkos S; Westermark K; Sepodes B
Drug Discov Today; 2018 Jan; 23(1):90-100. PubMed ID: 29024805
[TBL] [Abstract][Full Text] [Related]
39. Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal process.
Takada S; Narukawa M
Int J Technol Assess Health Care; 2021 Dec; 38(1):e11. PubMed ID: 34933699
[TBL] [Abstract][Full Text] [Related]
40. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]